Veracyte (VCYT) Capital Expenditures (2012 - 2026)

Veracyte has disclosed Capital Expenditures across 15 years of filings, most recently posting $3.0 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $3.0 million, up 62.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (up 175.86% YoY), and the FY2025 annual result was $2.3 million, up 94.6% from the prior year.
• Capital Expenditures came in at $3.0 million for Q1 2026 at Veracyte, up from $1.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $9.5 million in Q4 2023 to a low of -$6.0 million in Q4 2024.
• The 5-year median for Capital Expenditures is $1.8 million (2025), against an average of $1.5 million.
• Across the five-year window, Capital Expenditures soared 418.56% in 2022 and tumbled 347.26% in 2023, its largest moves.
• Veracyte's Capital Expenditures stood at $1.9 million in 2022, then soared by 409.46% to $9.5 million in 2023, then slumped by 162.49% to -$6.0 million in 2024, then soared by 124.83% to $1.5 million in 2025, then jumped by 100.14% to $3.0 million in 2026.
• The last three Capital Expenditures figures came in at $3.0 million (Q1 2026), $1.5 million (Q4 2025), and $323000.0 (Q3 2025), per Business Quant data.